LLY Signals Potential Buying OpportunityEli Lilly and CompanyBATS:LLYfinvestnomicsLLY is seeing renewed buying interest after retracing to its 20-day and 50-day moving averages. The stock remains in an uptrend, making higher highs and higher lows while trading above both moving averages, signaling continued bullish momentum. Eli Lilly & Co. is a $1.18 trillion market-cap pharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of pharmaceutical products. Its portfolio spans diabetes, oncology, immunology, neuroscience, and other therapeutic areas. LLY is a wide-moat company with strong and consistent fundamental growth. Revenue and EPS have increased year over year in each of the last three quarters, with the most recent growth rates at 48% and 26%, respectively. The company has an operating margin of 54% and a net margin of 31%, while ROE and ROIC stand at 102% and 40%, respectively. Its current ratio of 1.4x and debt-to-equity ratio of 1.6x indicate a solid liquidity position, although leverage is relatively elevated. Looking ahead, both revenue and EPS are forecast to continue growing over the next three quarters, with 38% revenue growth and 73% EPS growth expected in the next quarter. The average analyst price target is approximately $1,348.74, representing about 7% upside potential.